Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors A C

Naoko Takebe, Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz, Elad Sharon, Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Li Chen, Ting Chia ChangBiswajit Das, Ganesh Mugundu, James H. Doroshow, Alice P. Chen

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors A C'. Together they form a unique fingerprint.

Medicine & Life Sciences